Zhi-yu Xia

No.1095 Jiefang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer.

First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: April 13, 2026

Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system.

Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system.

Journal: Journal for immunotherapy of cancer

Published: January 09, 2026

Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.

Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.

Journal: Prostate international

Published: July 24, 2025

Research progress of norcantharidin nanodrugs for tumor treatment.

Research progress of norcantharidin nanodrugs for tumor treatment.

Journal: Nanoscale

Published: July 18, 2025

Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database.

Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database.

Journal: Expert opinion on drug safety

Published: June 04, 2025

Real-world safety of irreversible electroporation therapy for tumors with nanoknife: MAUDE database analysis.

Real-world safety of irreversible electroporation therapy for tumors with nanoknife: MAUDE database analysis.

Journal: BMC surgery

Published: April 29, 2025

Stimuli-responsive peptide-based nanodrug delivery systems for tumor therapy.

Stimuli-responsive peptide-based nanodrug delivery systems for tumor therapy.

Journal: Chemical communications (Cambridge, England)

Published: April 28, 2025

Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer.

Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: March 28, 2025

A preliminary follow-up study on irreversible electroporation therapy in older patients with prostate cancer.

A preliminary follow-up study on irreversible electroporation therapy in older patients with prostate cancer.

Journal: Discover oncology

Published: November 02, 2024

Trends in focal therapy for localized prostate cancer: a bibliometric analysis from 2014 to 2023.

Trends in focal therapy for localized prostate cancer: a bibliometric analysis from 2014 to 2023.

Journal: Discover oncology

Published: July 26, 2024

A clinical evaluation of robotic-assisted radical prostatectomy (RARP) in located prostate cancer: A systematic review and network meta-analysis.

A clinical evaluation of robotic-assisted radical prostatectomy (RARP) in located prostate cancer: A systematic review and network meta-analysis.

Journal: Critical reviews in oncology/hematology

Published: May 06, 2024

A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance.

A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance.

Journal: Frontiers in immunology

Published: March 03, 2024

Showing 1-12 of 12

Last Updated: 09/26/2026